AI + EXCLUSIVE DATA

AI analyzes funding data you can't access anywhere else

Our proprietary AI monitors 15,000+ companies and identifies which funded companies need YOUR specific solution right now.

10-25 personalized leads daily • 92% average intent score • Smart feed technology

Start with:

✓Flexible Plans • $39/mo or $29/mo annual

✓AI + real-time funding intelligence

✓Never see duplicates in your feed

INDUSTRY FIRST

Evopoint Biosciences Secures $97M in Series E Round Led by Tencent and Guoxin for Medical Breakthroughs

Feb 21, 2024•over 1 year ago

Amount Raised

$97.4 Million

Round Type

series e

SuzhouBiotechnology

Investors

GicCicc CapitalOceanpine CapitalGuoxin InvestmentTencent Investment

Description

Evopoint Biosciences has secured a Series E funding round of 700 million yuan ($97.4 million), spearheaded by Tencent Investment and Guoxin Investment, to propel the company's ambitious clinical trials to new heights.

Company Information

Company

Evopoint Biosciences

Location

Suzhou, Jiangsu, China

About

Since its inception in 2017, Evopoint Biosciences has been at the forefront of medical innovation. With a robust pipeline of nine clinical candidates, including two in the critical Phase III of clinical development, the company has consistently pushed the boundaries of medical science. Specializing in oncology, anti-infectives, and metabolic diseases, Evopoint's research and development efforts have not only garnered attention but have also set the stage for potential groundbreaking treatments that could change the course of modern medicine.

FundzWatch™ Score

Medium Activity

Buyer Intent Analysis

Get personalized insights on buying likelihood

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech